pentobarbital and daridorexant both increase sedation. Modify Therapy/Observe Intently. Coadministration boosts risk of CNS depression, which may lead to additive impairment of psychomotor functionality and result in daytime impairment.
Sodium valproate and valproic acid show up to minimize barbiturate metabolism; consequently, barbiturate blood amounts really should be monitored and correct dosage adjustments produced as indicated.
pentobarbital will lessen the level or effect of felodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will lessen the level or effect of bazedoxifene/conjugated estrogens by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will minimize the extent or influence of piroxicam by impacting hepatic enzyme CYP2C9/10 metabolism. Minimal/Importance Unfamiliar.
pentobarbital will lower the level or result of eltrombopag by impacting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Keep track of.
pentobarbital will lessen the extent or outcome of fosamprenavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will decrease the extent or effect of tolterodine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will lower the extent or outcome of cinacalcet by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
buprenorphine transdermal and pentobarbital both increase sedation. Stay away from or Use Alternate Drug. Limit use to clients for whom alternate treatment selections are insufficient
Observe Intently (1)pentobarbital will decrease the extent or result of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, not enough efficacy or, quite possibly, growth of a withdrawal syndrome in a very patient who's got made Bodily dependence to fentanyl. After halting a CYP3A4 inducer, as being the effects from the inducer decrease, the fentanyl plasma focus will enhance which could improve or lengthen both the therapeutic and adverse effects.
pentobarbital will lessen the extent or result of isavuconazonium sulfate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will minimize the level or result of fosaprepitant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
Check Carefully (1)pentobarbital will lower the level or impact of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, advancement of a withdrawal syndrome within a individual who's got designed Bodily dependence to fentanyl. Soon after stopping a CYP3A4 inducer, since the effects in the inducer decline, the fentanyl plasma concentration will increase which could increase or lengthen both here the therapeutic and adverse effects.